



FORM PTO-1449

(REV. 2/72)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. 3745.234-US

Serial No. 09/754,723

Applicant Ole Kirk

Filing Date January 4, 2001

Group 1645

RECEIVED  
JUL 10 2003  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PAD	1	Opposition to European Patent No. 0631505 by Eli Lilly and Company, dated September 13, 2000;
PAD	2	Affidavit of Raymond J. Carroll submitted by Opponent Eli Lilly;
PAD	3	Affidavit of Gerald Gold submitted by Opponent Eli Lilly;
PAD	4	Observations of the Proprietor Novo Nordisk on the notice of opposition by Eli Lilly and Company, dated June 15, 2001;
PAD	5	Summons To Attend Oral Proceedings Pursuant to Rule 71(1) EPC, dated December 17, 2001;
PAD	6	Letter from Opponent Eli Lilly dated April 22, 2002 and accompanying Declaration of John M. Beals, Ph.D.;
PAD	7	Observations of the patent proprietor Novo Nordisk pursuant to Rule 71(a) EPC, dated April 24, 2002;
PAD	8	Declaration of Dr. Sturis submitted by Patent Proprietor Novo Nordisk;
PAD	9	Letter of Opponent Eli Lilly dated May 17, 2002;
PAD	10	Signed Statement of Dr. Patrik Rorsman submitted by Opponent Eli Lilly
PAD	11	Minutes of the oral proceedings before the Opposition Division on June 24, 2002.

EXAMINER

MARICIA A. DUFFY

DATE CONSIDERED

12/3/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.